Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.

doi:10.1186/s12885-020-07758-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.

BMC cancer - 14 Jan 2021

Martínez-Lago Nieves, Fernández-Montes Ana, Covela Marta, Brozos Elena M, De la Cámara Juan, Méndez Méndez José C, Jorge-Fernández Mónica, Cousillas Castiñeiras Antía, Reboredo Cristina, Arias Ron David, Pellón Augusto María L, González Villarroel Paula, Graña Begoña, Salgado Fernández Mercedes, Carral Maseda Alberto, Vázquez Rivera Francisca, Candamio Folgar Sonia, Reboredo López Margarita

Abstract excerpt

BACKGROUND: Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF V600-mutated mCRC. METHODS: This real-world, multicenter, retrospective,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Platelets

Share to Lymphocytes

Share to Neoplasm Metastasis

Share to Neutrophils

Share to Proto-Oncogene Proteins B-raf

Share to Spain

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33446148
DOI: 10.1186/s12885-020-07758-5
PMCID: PMC7807898

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.PMID 33446148Read ↗

Effect of Antiangiogenic-Based Treatment and Systemic Inflammatory Factors on Outcomes in Patients With BRAF v600-Mutated Metastatic Colorectal Cancer: A Real-World Study in SpainSemantic proximity Read ↗

Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 StudySemantic proximity Read ↗

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled AnalysisSemantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Prognostic Significance of mEASIX, Inflammatory–Nutritional Biomarkers, Metastatic Patterns, and Treatment Characteristics in Metastatic Melanoma: A Multicenter Real-World Cohort StudySemantic proximity Read ↗

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.Semantic proximity Read ↗

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis.Semantic proximity Read ↗

Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.Semantic proximity Read ↗

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.Semantic proximity Read ↗

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.